Details
Stereochemistry | RACEMIC |
Molecular Formula | C16H14O3 |
Molecular Weight | 254.2806 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C(O)=O)C1=CC=CC(=C1)C(=O)C2=CC=CC=C2
InChI
InChIKey=DKYWVDODHFEZIM-UHFFFAOYSA-N
InChI=1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)
Molecular Formula | C16H14O3 |
Molecular Weight | 254.2806 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: https://www.drugs.com/international/dexketoprofen.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/21052564Curator's Comment: Description was created based on several sources, including:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c2c99853-1268-4998-a44b-2bf0c0b70fd2
https://www.ncbi.nlm.nih.gov/pubmed/9626023
https://www.ncbi.nlm.nih.gov/pubmed/3526298
Sources: https://www.drugs.com/international/dexketoprofen.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/21052564
Curator's Comment: Description was created based on several sources, including:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c2c99853-1268-4998-a44b-2bf0c0b70fd2
https://www.ncbi.nlm.nih.gov/pubmed/9626023
https://www.ncbi.nlm.nih.gov/pubmed/3526298
Ketoprofen is a drug belonging to the family of non-steroidal anti-inflammatory drugs. Ketoprofen, was synthesized in France by Rhône-Poulenc chemists in 1967, and introduced in 1973 in France and the United Kingdom for antiinflammatory use. Ketoprofen selectively inhibits isoform-I of cyclo-oxygenase, COX-1. Ketoprofen has shown to be an excellent choice of drug for the treatment of chronic pain in patients with osteoarthritis, rheumatoid arthritis. In addition Ketoprofen is prescribed for management of pain (acute forms of pain, traumatic and post-surgical pain) and also indicated for treatment of primary dysmenorrhea
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4076328
Curator's Comment: https://www.ncbi.nlm.nih.gov/pubmed/2079099
Originator
Sources: ZA6800524https://www.ncbi.nlm.nih.gov/pubmed/3526298
Curator's Comment: 1967
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10841807 |
1.9 nM [IC50] | ||
Target ID: CHEMBL230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10841807 |
27.0 nM [IC50] | ||
Target ID: CHEMBL2096909 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15974585 |
50.0 nM [IC50] | ||
Target ID: CHEMBL230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14510637 |
0.52 µM [IC50] | ||
Target ID: CHEMBL221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14510637 |
0.019 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Keral Approved UseUnknown |
|||
Primary | Keral Approved UseUnknown |
|||
Primary | Keral Approved UseUnknown |
|||
Primary | KETOPROFEN Approved UseKetoprofen capsules USP are indicated for the management of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Ketoprofen capsules USP are indicated for the management of pain. Ketoprofen capsules USP are also indicated for treatment of primary dysmenorrhea. Launch Date7.2498243E11 |
|||
Primary | KETOPROFEN Approved UseKetoprofen capsules USP are indicated for the management of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Ketoprofen capsules USP are indicated for the management of pain. Ketoprofen capsules USP are also indicated for treatment of primary dysmenorrhea. Launch Date7.2489599E11 |
|||
Primary | KETOPROFEN Approved UseKetoprofen capsules USP are indicated for the management of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Ketoprofen capsules USP are indicated for the management of pain. Ketoprofen capsules USP are also indicated for treatment of primary dysmenorrhea. Launch Date7.2489599E11 |
|||
Primary | KETOPROFEN Approved UseKetoprofen capsules USP are indicated for the management of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Ketoprofen capsules USP are indicated for the management of pain. Ketoprofen capsules USP are also indicated for treatment of primary dysmenorrhea. Launch Date7.2489599E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10.1 μg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7439263 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
KETOPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
21.91 μg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7439263 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
KETOPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.13 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7439263 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
KETOPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
12.5 mg single, oral Dose: 12.5 mg Route: oral Route: single Dose: 12.5 mg Sources: Page: p. 34 |
unhealthy, 36.8 years (range: 18 - 65 years) n = 90 Health Status: unhealthy Age Group: 36.8 years (range: 18 - 65 years) Sex: M+F Population Size: 90 Sources: Page: p. 34 |
Disc. AE: Rash... AEs leading to discontinuation/dose reduction: Rash (mild, 1 patient) Sources: Page: p. 34 |
2400 mg single, oral Overdose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
unhealthy, 45 years Health Status: unhealthy Age Group: 45 years Sex: F Sources: |
Other AEs: Epigastric pain... Other AEs: Epigastric pain (mild, 1 patient) Sources: |
100 mg 1 times / day multiple, topical Dose: 100 mg, 1 times / day Route: topical Route: multiple Dose: 100 mg, 1 times / day Sources: |
unhealthy, adult n = 172 Health Status: unhealthy Condition: tendinitis Age Group: adult Population Size: 172 Sources: |
|
100 ug 3 times / day steady, oral (max) Dose: 100 ug, 3 times / day Route: oral Route: steady Dose: 100 ug, 3 times / day Sources: |
unhealthy n = 50 Health Status: unhealthy Condition: Lymphedema Population Size: 50 Sources: |
Other AEs: Cellulitis... Other AEs: Cellulitis (below serious, 3 patients) Sources: |
75 ug 3 times / day steady, oral Dose: 75 ug, 3 times / day Route: oral Route: steady Dose: 75 ug, 3 times / day Sources: |
unhealthy n = 19 Health Status: unhealthy Condition: Lymphedema Population Size: 19 Sources: |
Other AEs: Rash... |
75 ug 3 times / day steady, oral Dose: 75 ug, 3 times / day Route: oral Route: steady Dose: 75 ug, 3 times / day Sources: |
unhealthy n = 23 Health Status: unhealthy Condition: Lymphedema Population Size: 23 Sources: |
Other AEs: Cellulitis... Other AEs: Cellulitis (below serious, 1 patient) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Rash | mild, 1 patient Disc. AE |
12.5 mg single, oral Dose: 12.5 mg Route: oral Route: single Dose: 12.5 mg Sources: Page: p. 34 |
unhealthy, 36.8 years (range: 18 - 65 years) n = 90 Health Status: unhealthy Age Group: 36.8 years (range: 18 - 65 years) Sex: M+F Population Size: 90 Sources: Page: p. 34 |
Epigastric pain | mild, 1 patient | 2400 mg single, oral Overdose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: |
unhealthy, 45 years Health Status: unhealthy Age Group: 45 years Sex: F Sources: |
Cellulitis | below serious, 3 patients | 100 ug 3 times / day steady, oral (max) Dose: 100 ug, 3 times / day Route: oral Route: steady Dose: 100 ug, 3 times / day Sources: |
unhealthy n = 50 Health Status: unhealthy Condition: Lymphedema Population Size: 50 Sources: |
Rash | below serious, 1 patient | 75 ug 3 times / day steady, oral Dose: 75 ug, 3 times / day Route: oral Route: steady Dose: 75 ug, 3 times / day Sources: |
unhealthy n = 19 Health Status: unhealthy Condition: Lymphedema Population Size: 19 Sources: |
Cellulitis | below serious, 1 patient | 75 ug 3 times / day steady, oral Dose: 75 ug, 3 times / day Route: oral Route: steady Dose: 75 ug, 3 times / day Sources: |
unhealthy n = 23 Health Status: unhealthy Condition: Lymphedema Population Size: 23 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes [IC50 1.3 uM] | ||||
yes [IC50 1.4 uM] | ||||
yes [IC50 11.9 uM] | ||||
yes [IC50 400 uM] | ||||
yes [IC50 5.98 uM] | ||||
yes [IC50 70.3 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/19422321/ Page: 2.0 |
minor | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15843492/ Page: 8.0 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15843492/ Page: 8.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15843492/ Page: 8.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15843492/ Page: 8.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15843492/ Page: 8.0 |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Modeling cyclooxygenase inhibition. Implication of active site hydration on the selectivity of ketoprofen analogues. | 2000 Jun 1 |
|
Iatrogenic cost factors incorporating mild and moderate adverse events in the economic comparison of aceclofenac and other NSAIDs. | 2001 |
|
Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. | 2001 |
|
Use of continuous fluid drainage for severe polyhydramnios due to twin to twin transfusion syndrome. | 2001 |
|
[Two complex suicidal poisonings with drugs and their medicolegal aspects]. | 2001 |
|
Early-morning administration of dexketoprofen-trometamol in morning stiffness induced by nodal osteoarthritis of the hands. | 2001 |
|
Release behavior of ketoprofen from poly(acryloyl-L-proline methyl ester) gels having different crosslinked networks. | 2001 |
|
Overdose of ketoprofen could be dangerous. | 2001 Apr |
|
Interaction between the antinociceptive effect of ketoprofen and adrenergic modulatory systems. | 2001 Aug |
|
Simultaneous optimization based on artificial neural networks in ketoprofen hydrogel formula containing O-ethyl-3-butylcyclohexanol as percutaneous absorption enhancer. | 2001 Aug |
|
Binding constant determination of drugs toward subdomain IIIA of human serum albumin by near-infrared dye-displacement capillary electrophoresis. | 2001 Aug |
|
Investigation of the utility of an in vitro release test for optimizing semisolid dosage forms. | 2001 Aug |
|
Sustained release ketoprofen microparticles with ethylcellulose and carboxymethylethylcellulose. | 2001 Aug 10 |
|
In vitro distribution of ketoprofen enantiomers in articular tissues of osteoarthritic patients. | 2001 Dec |
|
Oral ketoprofen in children--could it have been done differently? | 2001 Jan |
|
Cytokines and cytokine inducers stimulate prostaglandin E2 entry into the brain. | 2001 Jul |
|
Comparison of tissue concentrations after intramuscular and topical administration of ketoprofen. | 2001 Jul |
|
[Enantiomeric separation of drugs based on macrocyclic antibiotics]. | 2001 Jul |
|
Analgesic profile of peroral and topical ketoprofen upon low pH-induced muscle pain. | 2001 Jul |
|
Enantioselective inhibition of the binding of rac-profens to human serum albumin induced by lithocholate. | 2001 Jul |
|
Evaluation of percutaneous absorption and skin irritation of ketoprofen through rat skin: in vitro and in vivo study. | 2001 Jul 17 |
|
Stereoselective pharmacokinetics of ketoprofen in llamas following intravenous administration. | 2001 Jun |
|
Enantiospecific pharmacokinetics of ketoprofen in plasma and synovial fluid of horses with acute synovitis. | 2001 Jun |
|
Safety and efficacy of preoperative administration of meloxicam, compared with that of ketoprofen and butorphanol in dogs undergoing abdominal surgery. | 2001 Jun |
|
Simultaneous photocontact sensitivity to ketoprofen and oxybenzone. | 2001 Jun |
|
Simultaneous determination of loxoprofen and its diastereomeric alcohol metabolites in human plasma and urine by a simple HPLC-UV detection method. | 2001 Jun |
|
[Acute pancreatitis and ketoprofen]. | 2001 Jun-Jul |
|
[Ketoprofen-induced acute hepatitis]. | 2001 Jun-Jul |
|
I.v. ketoprofen for analgesia after tonsillectomy: comparison of pre- and post-operative administration. | 2001 Mar |
|
Thoracoscopy as a nonpharmacotherapeutic research modification for limiting postoperative chest pain. | 2001 Mar-Apr |
|
Effect of oxidative stress on the structure and function of human serum albumin. | 2001 May |
|
Chiral resolution of flurbiprofen and ketoprofen enantiomers by HPLC on a glycopeptide-type column chiral stationary phase. | 2001 May |
|
Screening procedure for detection of non-steroidal anti-inflammatory drugs and their metabolites in urine as part of a systematic toxicological analysis procedure for acidic drugs and poisons by gas chromatography-mass spectrometry after extractive methylation. | 2001 May-Jun |
|
Onset of analgesia for liquigel ibuprofen 400 mg, acetaminophen 1000 mg, ketoprofen 25 mg, and placebo in the treatment of postoperative dental pain. | 2001 Nov |
|
Measurement of ketoprofen in horse urine using gas chromatography-mass spectrometry. | 2001 Oct |
|
Influence of betacyclodextrin on the release of poorly soluble drugs from inert and hydrophilic heterogeneous polymeric matrices. | 2001 Oct |
|
Lipopolysaccharide-induced increase of prostaglandin E(2) is mediated by inducible nitric oxide synthase activation of the constitutive cyclooxygenase and induction of membrane-associated prostaglandin E synthase. | 2001 Oct 1 |
|
Effects of diclofenac and ketoprofen on nerve conduction velocity in experimental nerve root compression. | 2001 Oct 15 |
|
Optimized conditions of bio-mimetic artificial membrane permeation assay. | 2001 Oct 9 |
|
Transdermal delivery of ketoprofen using microemulsions. | 2001 Oct 9 |
|
[ Ambulatory laparoscopic gynecological surgery in Africa: feasibility]. | 2001 Sep |
|
Efficacy and safety of ketoprofen lysine salt mouthwash versus benzydamine hydrochloride mouthwash in acute pharyngeal inflammation: a randomized, single-blind study. | 2001 Sep |
|
Comparison of the effects of ketoprofen on platelet function in the presence and absence of aspirin. | 2001 Sep |
|
Promoting mechanism of menthol derivative, 1-O-ethyl-3-buthylcyclohexanol, on the percutaneous absorption of ketoprofen. | 2001 Sep |
|
Incompatibility of prochlorperizine and ketoprofen. | 2001 Sep |
|
Photocontact dermatitis to ketoprofen. | 2001 Sep |
|
Antihyperalgesic effects of the muscarinic receptor ligand vedaclidine in models involving central sensitization in rats. | 2001 Sep |
|
Functional characterization of rat organic anion transporter 2 in LLC-PK1 cells. | 2001 Sep |
|
In vitro and in vivo evaluation of polyoxyethylene esters as dermal prodrugs of ketoprofen, naproxen and diclofenac. | 2001 Sep |
|
Enhancement of the activity of doxorubicin by inhibition of glutamate transporter. | 2001 Sep 15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02568735
intravenous: 0,5 mg/kg up to 50 mg
oral: 5 - 100 mg
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9176993
Curator's Comment: In cultivation of freshly isolated epidermal cells, 5 mM Ketoprofen inhibited the culture-promoted expression of PCl-augmented expression of major histocompatibility complex class II and CD86 on Langerhans cells
Male Sprague-Dawley rats (180–230 g) were killed by ether anesthesia, and brains without cerebellum were rapidly excised. Organs were washed in icecold saline and then cut into small tissue fragments (about 1–3 mm^3). Fragments of one-half of the brain (500 mg) were incubated in 3.0 ml of oxygenated Tyrode solution (pH 7.4) at 37°C for 10 min in the presence of the inhibitor (Dexketoprofen 4-1000nM) or vehicle. Incubations were terminated by brief centrifugation to remove tissue fragments. The resulting supernatants were stored at −80°C until levels of PGF2a were determined by a specific competitive enzyme immunoassay
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 21:51:42 UTC 2022
by
admin
on
Fri Dec 16 21:51:42 UTC 2022
|
Record UNII |
90Y4QC304K
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
M01AE03
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
||
|
WHO-VATC |
QM01AE53
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
||
|
WHO-VATC |
QM01AE03
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
||
|
NDF-RT |
N0000175722
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
||
|
LIVERTOX |
NBK548678
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
||
|
NDF-RT |
N0000175721
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
||
|
WHO-ATC |
M02AA10
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
||
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
||
|
NDF-RT |
N0000000160
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
||
|
WHO-VATC |
QM02AA10
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
||
|
CFR |
21 CFR 522.1225
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
||
|
WHO-ATC |
M01AE53
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6128
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
PRIMARY | |||
|
3284
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
PRIMARY | |||
|
KETOPROFEN
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
PRIMARY | |||
|
3825
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
PRIMARY | |||
|
90Y4QC304K
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
PRIMARY | |||
|
172964-50-0
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
SUPERSEDED | |||
|
SUB08374MIG
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
PRIMARY | |||
|
M6622
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
PRIMARY | Merck Index | ||
|
Ketoprofen
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
PRIMARY | |||
|
1528
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
PRIMARY | |||
|
22161-86-0
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
SUPERSEDED | |||
|
758144
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
PRIMARY | |||
|
C47578
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
PRIMARY | |||
|
90Y4QC304K
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
PRIMARY | |||
|
CHEMBL571
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
PRIMARY | |||
|
244-759-8
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
PRIMARY | |||
|
6142
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
PRIMARY | RxNorm | ||
|
22071-15-4
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
PRIMARY | |||
|
154907-35-4
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
SUPERSEDED | |||
|
DB01009
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
PRIMARY | |||
|
D007660
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
PRIMARY | |||
|
1356632
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
PRIMARY | |||
|
DTXSID6020771
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
PRIMARY | |||
|
4795
Created by
admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
ENANTIOMER -> RACEMATE | |||
|
TRANSPORTER -> INHIBITOR | |||
|
ENANTIOMER -> RACEMATE | |||
|
SALT/SOLVATE -> PARENT | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
SALT/SOLVATE -> PARENT | |||
|
BINDER->LIGAND |
BINDING
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
USP
|
||
|
TRANSPORTER -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||